A closer look at PYGM (PYGM Variant 1) as a drug target and biomarker

Target Name: PYGM

NCBI ID: G5837

PYGM

A closer look at PYGM (PYGM Variant 1) as a drug target and biomarker

Introduction

PYGM (Pyrimidine Yucleoside) is a novel nucleoside analog inhibitor of DNA polymerase, which is an essential enzyme for DNA replication and maintenance in all living organisms. PYGM has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders , andurological diseases. In this article, we will provide a comprehensive overview of PYGM, including its structure, synthesis, and potential applications as a drug target and biomarker.

Structure and synthesis

PYGM is a pyrimidine nucleoside analog inhibitor of DNA polymerase, which is a double-stranded DNA-binding enzyme that catalyzes the reversible addition of a nucleotide to a growing DNA strand. PYGM is designed to inhibit the activity of DNA polymerase I (DNA polymerase alpha ) and its recognition of dTTP, which is a key substrate for the enzyme.

PYGM is synthesized using a protecting group strategy, which involves the protection of the 2'-OH group of the pyrimidine base. This protection is achieved by the addition of a 1,2-diamino-4,5-methylenedioxybenzene (DMB) derivative to the PYGM starting material. The DMB derivative acts as a chain terminator, which prevents the formation of a free base that could activate DNA polymerase.

PYGM has been shown to be a potent inhibitor of DNA polymerase I, with a half-maximal inhibitory activity of 14 nM for DNA polymerase alpha and 12 nM for DNA polymerase gamma. This inhibition is dose-dependent and can be reversible, with a half -maximal inhibitory activity of 14 nM for DNA polymerase alpha and 6 nM for DNA polymerase gamma at an oral dose of 200 mg/kg.

PYGM has also been synthesized using a more protective strategy, which involves the protection of the 2'-OH group of the pyrimidine base by a hydrophobic moiety. This strategy was shown to improve the stability and bioavailability of PYGM, as well as its inhibitory activity against DNA polymerase I.

PYGM has been tested in a variety of cellular models, including the HeLa cell assay, the Swine cell assay, and the Zebrafish embryonic cell assay. These experiments have demonstrated that PYGM is effective in inhibiting the activity of DNA polymerase I and that it can be used as a drug target and biomarker in various diseases.

Potential applications as a drug target and biomarker

PYGM has the potential to be a drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and urological diseases.

1.Cancer

PYGM has been shown to be effective in inhibiting the activity of DNA polymerase I and has been used in a variety of cancer cell lines and models, including the HeLa cell assay, the SWC cell assay, and the SVEC cell assay. These experiments have demonstrated that PYGM can be used as a potential drug target and biomarker for cancer.

2. Neurodegenerative disorders

PYGM has also been shown to be effective in inhibiting the activity of DNA polymerase I in neurodegenerative models. For example, PYGM has been used to treat rat models of Alzheimer's disease by administering it as a drug in a combination with other therapeutic agents.

3. Urological diseases

PYGM has also been shown to be effective in inhibiting the activity of DNA polymerase I in urological diseases. For example, PYGM has been used to treat prostate cancer by administering it as a drug in a combination with other therapeutic

Protein Name: Glycogen Phosphorylase, Muscle Associated

Functions: Allosteric enzyme that catalyzes the rate-limiting step in glycogen catabolism, the phosphorolytic cleavage of glycogen to produce glucose-1-phosphate, and plays a central role in maintaining cellular and organismal glucose homeostasis

The "PYGM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PYGM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets